Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia
NCT ID: NCT00565890
Last Updated: 2013-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2005-12-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia
NCT01306227
Antithyroid Drug Treatment of Thyrotoxicosis in Young People
NCT01436994
ASQ Scores of Transient Hypothyroxinemia of Prematurity
NCT05901623
A Clinical Study of Hyperthyroidism in Children
NCT06570967
Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
NCT00388297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
No replacement therapy
thyroxine
thyroxine at the dose of 5 μg/kg-wt /day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
thyroxine
thyroxine at the dose of 5 μg/kg-wt /day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestation: 22 weeks 0 day ≤
* Serum free thyroxine level lower than 0.8 ng/dl
* Serum thyrotropin lower than 10 μU/ml
* Age of between 2 and 4 weeks after birth
* Informed consent
Exclusion Criteria
2 Weeks
4 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tokyo Metropolitan Bokuto Hospital
UNKNOWN
Tokyo Women's Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Satoshi Kusuda
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Satoshi Kusuda, MD
Role: PRINCIPAL_INVESTIGATOR
Tokyo Women's Medical Unversity
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maternal and Perinatal Center, Tokyo Women's Medical University
Tokyo, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T4VLBWI
Identifier Type: -
Identifier Source: secondary_id
nrntokyo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.